European Pharmaceutical Review
DECEMBER 15, 2023
Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. The post Positive results for mRNA vaccine in melanoma patients appeared first on European Pharmaceutical Review.
Pharmaceutical Technology
OCTOBER 14, 2022
German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 23, 2022
The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.
Pharmaceutical Technology
AUGUST 17, 2022
These programmes will include therapies and vaccines in infectious disease and oncology areas. Preclinical data showed the potential of oRNA expression and delivery as a method for advanced development in various areas, including vaccines and oncology treatments. Topic sponsors are not involved in the creation of editorial content.
European Pharmaceutical Review
AUGUST 18, 2022
Merck (MSD outside of the US and Canada) has entered into a collaboration agreement with Orna Therapeutics to discover, develop and commercialise multiple programmes of engineered circular RNA (oRNA) therapies, including vaccines and therapeutics in the areas of infectious disease and oncology.
Pharmaceutical Technology
JULY 13, 2022
Merck Research Laboratories president Dr Dean Li said: “Targeting CYP11A1 provides a compelling approach to suppressing the production of steroid hormones, a key driver of prostate cancer. “We The latest deal complements and bolsters the oncology pipeline of Merck.
European Pharmaceutical Review
JANUARY 16, 2023
The safety and efficacy of mRNA vaccines should be a game changer and is the likely solution to antibiotic-resistant microorganisms and emerging viral pathogens.” The previous record for vaccine development and approval was four years for the measles vaccine. Perhaps we will see a universal flu vaccine in the near future.
Expert insights. Personalized for you.
96 
Let's personalize your content